Phase 2 Study

BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia in adults with Alpha (α)-Thalassemia.

Edit

Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for ...

Hastings Tribune 18 Feb 2026

TOKYO--(BUSINESS WIRE)--Feb 18, 2026-- ... .

Edit

Asahi Kasei Pharma and Alchemedicine announce initiation of Phase I study of selective endothelin A receptor antagonist AK1960 (Asahi Kasei Corporation)

Public Technologies 18 Feb 2026

). February 18, 2026. Asahi Kasei Pharma Corp ... Asahi Kasei Pharma and Alchemedicine today announced that Asahi Kasei Pharma has initiated a Phase I study in Japan for AK1960, a selective endothelin A receptor antagonist discovered by Alchemedicine ... News.

Edit

Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases

Pharmiweb 18 Feb 2026

The initiation of a Phase I study is considered a significant step toward growing Asahi Kasei’s healthcare impact ... While preclinical and Phase I studies are performed in Japan, the program is intended for the global market.

Edit

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in ...

Nasdaq Globe Newswire 17 Feb 2026

... study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).

Edit

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Business Wire 17 Feb 2026

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 ... .

Edit

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of ...

Business Wire 17 Feb 2026

RLYB), a clinical-stage biotechnology company translating scientific advances into transformative ...

Edit

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy ...

Nasdaq Globe Newswire 17 Feb 2026

NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced ...

Edit

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Pharmiweb 17 Feb 2026

“The results from our Phase 1 study of RLYB116 are both validating and highly encouraging, reinforcing our belief that this program has the potential to be a best-in-class therapeutic.

Edit

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer (Form 6-K) (NovaBridge Biosciences)

Public Technologies 17 Feb 2026

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer • Global, randomized Phase 2 study to ...

Edit

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer (NovaBridge Biosciences)

Public Technologies 17 Feb 2026

) Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first ...

Podcasts:

Latest News for: phase 2 study

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in ...

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination ...

AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic ...

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for ...

Asahi Kasei Pharma and Alchemedicine announce initiation of Phase I study of selective endothelin A receptor antagonist AK1960 (Asahi Kasei Corporation)

Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in ...

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of ...

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy ...

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer (Form 6-K) (NovaBridge Biosciences)

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer (NovaBridge Biosciences)

Article Search

EXPLORE WN.com